FUNDAMENTALS · Fundamentals · US Healthcare

Xilio Therapeutics (XLO) Fundamentals 2026 — Revenue Analysis | SniperIQ

Xilio Therapeutics (XLO) is a US-listed Healthcare company in Biotechnology with a market capitalization of $57M, trading at $8.61 on the NASDAQ. This SniperIQ fundamentals page covers Xilio Therapeutics's valuation, profitability (net margin -58.5%), revenue ($44M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$57M
Net Margin-58.5%
Revenue (FY25)$44M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Xilio Therapeutics's market cap?

Xilio Therapeutics (XLO) has a market capitalization of approximately $57M, trading at $8.61 on the NASDAQ. Market cap moves with the live share price.

What is Xilio Therapeutics's P/E ratio?

Xilio Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 19.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Xilio Therapeutics?

Xilio Therapeutics runs a net profit margin of -58.5%, a gross margin of 70.7%, and an operating margin of -79.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Xilio Therapeutics generate?

Xilio Therapeutics reported revenue of $44M for fiscal year 2025, with net income of -

5M and earnings per share (EPS) of -4.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Xilio Therapeutics pay a dividend?

Xilio Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Xilio Therapeutics financially healthy?

Xilio Therapeutics carries a debt-to-equity ratio of 0.09x and a current ratio of 3.59x, with a market beta of -0.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Xilio Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Xilio Therapeutics (XLO) the key facts are: market cap $57M, revenue $44M, 52-week range 6.468-12.74. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Xilio Therapeutics's full fundamentals live

Get Xilio Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.